Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H22FN3O3 |
Molecular Weight | 359.3947 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCN(CC1)C2=CC3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O
InChI
InChIKey=SPFYMRJSYKOXGV-UHFFFAOYSA-N
InChI=1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)
Molecular Formula | C19H22FN3O3 |
Molecular Weight | 359.3947 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM062413.pdfCurator's Comment: description was created based on several sources, including, http://file.scirp.org/pdf/OJVM_2016022615035704.pdf, https://actualidadveterinaria.files.wordpress.com/2011/10/fluoroquinolones-then-and-now.pdf
Sources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM062413.pdf
Curator's Comment: description was created based on several sources, including, http://file.scirp.org/pdf/OJVM_2016022615035704.pdf, https://actualidadveterinaria.files.wordpress.com/2011/10/fluoroquinolones-then-and-now.pdf
Enrofloxacin was developed by Bayer for the treatment of broad spectrum of bacterial infections in animals (cats and dogs). The drug exerts its action by inhibiting DNA Topoisomerase II (Gyrase) and DNA Topoisomerase IV (Topo IV), two major bacterial topoisomerase. Enrofloxacin was shown to be metabolized to ciprofloxacin and may cross the blood brain barrier in the animals.
Originator
Sources: http://www.baytril.com/en/home/history/
Curator's Comment: Enrofloxacin was synthesized by Bayer researchers Grohe and Peterson in 1980 # Bayer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311224 Sources: http://file.scirp.org/pdf/OJVM_2016022615035704.pdf |
|||
Target ID: CHEMBL2363076 Sources: http://file.scirp.org/pdf/OJVM_2016022615035704.pdf |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | BAYTRIL Approved UseBaytril Antibacterial Tablets and Injectable Solution are indicated for the management of diseases in dogs and cats associated with bacteria susceptible to enrofloxacin. Launch Date1.14048002E12 |
PubMed
Title | Date | PubMed |
---|---|---|
Interaction of fluoroquinolones and certain ionophores in broilers: effect on blood levels and hepatic cytochrome p450 monooxygenase activity. | 2001 |
|
Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. | 2001 Apr |
|
Determination of fluoroquinolones in serum using an on-line clean-up column coupled to high-performance immunoaffinity-reversed-phase liquid chromatography. | 2001 Apr 15 |
|
Effects of the matrix and sample preparation on the determination of fluoroquinolone residues in animal tissues. | 2001 Apr 20 |
|
In vitro susceptibility of avian mycoplasmas to enrofloxacin, sarafloxacin, tylosin, and oxytetracycline. | 2001 Apr-Jun |
|
Multiresidue analysis of fluoroquinolone antibiotics in chicken tissue using automated microdialysis-liquid chromatography. | 2001 Aug |
|
Determination of residues of enrofloxacin and its metabolite ciprofloxacin in biological materials by capillary electrophoresis. | 2001 Aug 5 |
|
Susceptibility of Arcobacter butzleri isolates to 23 antimicrobial agents. | 2001 Dec |
|
Information on adverse drug reaction in cats. | 2001 Dec 15 |
|
Epidemiological studies of human and animal Salmonella typhimurium DT104 and DT104b isolates in Ireland. | 2001 Feb |
|
Antibiotic resistance from down on the chicken farm. | 2001 Jan-Feb |
|
Pathogenicity and drug susceptibility of the Pasteurella anatis isolated in chickens in Taiwan. | 2001 Jul-Sep |
|
The effect of organic acids on the control of post-weaning oedema disease of piglets. | 2001 Jun |
|
In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs. | 2001 Jun |
|
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998. | 2001 Mar |
|
Development of an indirect competitive ELISA for ciprofloxacin residues in food animal edible tissues. | 2001 Mar |
|
In vitro evidence for effects of magnesium supplementation on quinolone-treated horse and dog chondrocytes. | 2001 Mar |
|
A microbiological six-plate method for the identification of certain antibiotic groups in incurred kidney and muscle samples. | 2001 May |
|
In vitro antibiotic sensitivity of strains of Ornithobacterium rhinotracheale isolated in The Netherlands between 1996 and 1999. | 2001 Nov 17 |
|
Prevalence and mechanism of resistance against macrolides and lincosamides in Streptococcus suis isolates. | 2001 Nov 26 |
|
Bioequivalence of four preparations of enrofloxacin in poultry. | 2001 Oct |
|
Absorption spectra of the 4f electron transitions of the praseodymium complex with 1-cyclopropyl-6-fluoro-1,4-dihydro-7-(4-ethyl-1-piperazinyl) -4-oxo-3-quinoline carboxylic acid hydrochloride and its analytical application. | 2001 Sep |
|
Antimicrobial susceptibility of Pasteurella multocida isolated from cattle and pigs. | 2001 Sep |
|
Effect of enrofloxacin treatment on plasma endotoxin during bovine Escherichia coli mastitis. | 2002 Apr |
|
Salmonella enterica serotype Typhimurium DT 104 antibiotic resistance genomic island I in serotype paratyphi B. | 2002 Apr |
|
Serovars of Salmonella isolated from Danish turkeys between 1995 and 2000 and their antimicrobial resistance. | 2002 Apr 13 |
|
Questions study on Escherichia coli susceptibility. | 2002 Apr 15 |
|
Multiresidue determination of (fluoro)quinolone antibiotics in swine kidney using liquid chromatography-tandem mass spectrometry. | 2002 Apr 5 |
|
Anticryptosporidial prophylactic efficacy of enrofloxacin and paromomycin in chickens. | 2002 Feb |
|
Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. | 2002 Feb |
|
Prevalence and antibiotic susceptibility of Salmonella isolated from beef animal hides and carcasses. | 2002 Feb |
|
History and clinical signs. | 2002 Feb |
|
Elimination of mycoplasma from leukemia-lymphoma cell lines using antibiotics. | 2002 Feb |
|
Monoclonal-based enzyme-linked immunosorbent assay and immunochromatographic assay for enrofloxacin in biological matrices. | 2002 Jan |
|
Blindness now attributed to enrofloxacin therapy in a previously reported case of a cat with acromegaly treated by cryohypophysectomy. | 2002 Jan |
|
Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. | 2002 Jan |
|
Spectrophotometric determination of ciprofloxacin, enrofloxacin and pefloxacin through charge transfer complex formation. | 2002 Jan 1 |
|
Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections. | 2002 Jan 15 |
|
Antibiotic resistance. Livestock feed ban preserves drugs' power. | 2002 Jan 4 |
|
Use of enrofloxacin for treatment of large-form Haemobartonella felis in experimentally infected cats. | 2002 Jul 15 |
|
Antimicrobial multiresistance in bacteria isolated from freshwater Chilean salmon farms. | 2002 Jul 3 |
|
Identification and antimicrobial susceptibility of Staphylococcus chromogenes isolates from intramammary infections of dairy cows. | 2002 Jun 20 |
|
Molecular epidemiology of feline bordetellosis in two animal shelters in California, USA. | 2002 Jun 25 |
|
Concentration of enrofloxacin and its metabolite ciprofloxacin in canine matrices of the locomotor system. | 2002 Mar |
|
Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Escherichia coli, and Salmonella choleraesuis recovered from Taiwanese swine. | 2002 Mar |
|
Feline visual changes associated with enrofloxacin. | 2002 Mar |
|
Ciprofloxacin resistance in Campylobacter jejuni evolves rapidly in chickens treated with fluoroquinolones. | 2002 Mar 15 |
|
Administration of enrofloxacin and capsaicin to chickens to achieve higher maximal serum concentrations. | 2002 Mar 16 |
|
Bacterial colonization of intravenous catheters in young dogs suspected to have parvoviral enteritis. | 2002 May 1 |
|
Sero types, phage types and antibiotic susceptibilities of Salmonella strains isolated from horses in The Netherlands from 1993 to 2000. | 2002 May 1 |
Patents
Sample Use Guides
The dose range of Baytril (Enrofloxacin) Antibacterial Tablets in dogs and cats is 5 to 20 mg/kg (2.27 to 9.07 mg/lb) of body weight, either as a single dose or divided into two (2) equal daily doses administered at twelve (12) hour intervals. The dose of Baytril Injectable Solution for dogs is 2.5 mg/kg (1.13 mg/lb) as a single injection. The injectable dose should be followed by oral tablet treatment in 12 hours.
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/12801456
The minimum inhibitory concentration (MIC) enrofloxacin against 24 Sicilian isolates of Mycoplasma agalactiae, the causative organism of contagious agalactia were determined in vitro by a broth dilution method. Enrofloxacin was effective antimicrobial in vitro with a range of MIC values from 0.125 to 0.500 microg/ml and an MIC(50) of 0.203 and MIC(90) of 0.365 microg/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 18:00:21 UTC 2022
by
admin
on
Fri Dec 16 18:00:21 UTC 2022
|
Record UNII |
3DX3XEK1BN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QJ01MA90
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
||
|
CFR |
21 CFR 556.226
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
||
|
CFR |
21 CFR 520.812
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
||
|
CFR |
21 CFR 524.802
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
||
|
NCI_THESAURUS |
C795
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
||
|
CFR |
21 CFR 522.812
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Enrofloxacin
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
71188
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
3DX3XEK1BN
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
24192
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | RxNorm | ||
|
C72660
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
758616
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
5963
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
Z-54
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
6952
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
DTXSID1045619
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
93106-60-6
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
CHEMBL15511
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
DB11404
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
C052904
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
M4916
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | Merck Index | ||
|
3DX3XEK1BN
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
1235900
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY | |||
|
35720
Created by
admin on Fri Dec 16 18:00:21 UTC 2022 , Edited by admin on Fri Dec 16 18:00:21 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |